We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diagnostic Options When Standard Tests Are Inconclusive

By LabMedica International staff writers
Posted on 18 Oct 2017
The diagnosis of Cushing’s disease, the predominant endogenous form of Cushing’s syndrome, requires a laboratory strategy that sequentially rules out potential causes of excess cortisol until the correct one is identified.

After ruling out exogenous causes of Cushing’s-like symptoms, the first step is to document cortisol excess. Blood cortisol concentration exhibits diurnal variation, so it is less useful than 24-hour urinary free cortisol, which the Endocrine Society (Washington, DC, USA) recommends for demonstrating overproduction of the hormone.

The other two recommended screening tests are salivary cortisol and the 1 mg overnight dexamethasone suppression test. If two of these three screening tests are abnormal, further investigation should be undertaken. If elevated adrenocorticotropic hormone (ACTH) is detected, this suggests an ACTH-dependent form of Cushing’s syndrome. About 30% of Cushing’s syndrome cases are ACTH-independent, but among ACTH-dependent cases, nearly all are caused by an ACTH-secreting pituitary adenoma and classified as Cushing’s disease. The remainder of ACTH-dependent cases is due to ectopic ACTH producing tumors, which are very rare and usually occur in the lungs or thymus, although they have also been described in the thyroid, ovaries, liver, and adrenal glands.

A high-dose dexamethasone suppression test helps determine if the case is Cushing’s disease or caused by ectopic ACTH production. High doses of dexamethasone often suppress ACTH production by pituitary adenomas, whereas no suppression occurs in ectopic tumors. Stimulation with corticotropin releasing hormone (CRH) also tends to exaggerate ACTH release in Cushing’s disease, whereas ectopic tumors respond poorly or not at all. In a small fraction of cases, however, the results of all of these tests are non-diagnostic. When this occurs, bilateral inferior petrosal sinus sampling (BIPSS) is needed to verify that the source of ACTH is the pituitary gland.

It has been reported that in patients with an ectopic ACTH producing tumor, the ratio of IPS: venous ACTH concentrations will be less than 1.4:1. In patients with Cushing’s disease, the ratio will exceed 2.0, with averages near 15. The sensitivity and specificity of BIPSS for Cushing’s disease are 88%-100% and 67%-100%, respectively. A less invasive procedure, jugular vein sampling (JVS), has been proposed. JVS has similar sensitivity and specificity to BIPSS, but when JVS results are negative, BIPSS is still recommended as the definitive test. The review written by Roger L. Bertholf, PhD, DABCC, FACB, from Houston Methodist Hospital in Texas (TX, USA) was published on October 1, 2017, in Clinical Laboratory News.

Related Links:
Endocrine Society
Houston Methodist Hospital


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Coagulation Analyzer
CS-2400
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.